Last10K.com

Jaguar Health, Inc. (JAGX) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023

SEC Filings

JAGX Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

JAGX Annual Reports

JAGX Quarterly Reports

JAGX Corporate News

JAGX Registration of Securities

Jaguar Health, Inc.

HISTORY TOOLS
CIK: 1585608 Ticker: JAGX
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Apr. 01, 2024
Jun. 30, 2023
Document and Entity Information   
Document Type10-K  
Document Annual Reporttrue  
Document Period End DateDec. 31, 2023  
Document Transition Reportfalse  
Entity File Number001-36714  
Entity Registrant NameJAGUAR HEALTH, INC.  
Entity Incorporation, State or Country CodeDE  
Entity Tax Identification Number46-2956775  
Entity Address, Address Line One200 Pine Street, Suite 400  
Entity Address, City or TownSan Francisco  
Entity Address, State or ProvinceCA  
Entity Address, Postal Zip Code94104  
City Area Code415  
Local Phone Number371-8300  
Title of 12(b) SecurityCommon Stock, Par Value $0.0001 Per Share  
Trading SymbolJAGX  
Security Exchange NameNASDAQ  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
ICFR Auditor Attestation Flagfalse  
Document Financial Statement Error Correctionfalse  
Entity Shell Companyfalse  
Entity Public Float  $ 9.9
Auditor NameRBSM LLP  
Auditor Firm ID587  
Auditor LocationLarkspur, California  
Entity Central Index Key0001585608  
Current Fiscal Year End Date--12-31  
Document Fiscal Year Focus2023  
Document Fiscal Period FocusFY  
Amendment Flagfalse  
Common stock - voting   
Document and Entity Information   
Entity Common Stock, Shares Outstanding 276,216,260 
Common stock - non-voting   
Document and Entity Information   
Entity Common Stock, Shares Outstanding 9 

View differences made from one year to another to evaluate Jaguar Health, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Jaguar Health, Inc..

Continue

Assess how Jaguar Health, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Jaguar Health, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Legal
M & A
Other
Filter Subcategory:
All
Geography
Product
Income
Expense
Debt
Cash Flow
Other
Inside Jaguar Health, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (Parenthetical)
Consolidated Statements Of Changes In Stockholders' Equity (Deficit)
Consolidated Statements Of Changes In Stockholders' Equity (Deficit) (Parenthetical)
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
Balance Sheet Components
Balance Sheet Components (Tables)
Balance Sheet Components - Accrued Liabilities (Details)
Balance Sheet Components - Amortization (Details)
Balance Sheet Components - Estimated Future Amortization Expense (Details)
Balance Sheet Components - Intangible Assets (Details)
Balance Sheet Components - Inventory And Prelaunch Inventory (Details)
Balance Sheet Components - Property And Equipment (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Details Of Office Space Lease (Details)
Commitments And Contingencies - Asset Transfer And Transition Commitment Update (Details)
Commitments And Contingencies - Commitments (Details)
Commitments And Contingencies - Joint Venture - Income Statement Information (Details)
Commitments And Contingencies - Master Services Agreement (Details)
Commitments And Contingencies - Purchase Commitment (Details)
Commitments And Contingencies - Revenue Sharing Commitment Update, Joint Venture And Legal Proceedings (Details)
Commitments And Contingencies - Undiscounted Cash Payment Obligation (Details)
Debt
Debt (Tables)
Debt - 2019 Tempesta Notes (Details)
Debt - Insurance Premium Financing (Details)
Debt - Notes Payable (Details)
Debt - Notes Payable - Future Maturities (Details)
Debt - Sale Of Future Royalty Interest (Details)
Debt - Streeterville Note (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Estimated Fair Value Of Level 3 (Details)
Fair Value Measurements - Fair Value Of Liabilities Measured On A Recurring Basis (Details)
Fair Value Measurements - Fair Value Option - Hybrid Instruments (Details)
Fair Value Measurements - Quantitative Information About The Significant Unobservable Inputs (Details)
Fair Value Measurements - Streeterville Note (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Net Operating Loss Carryover (Details)
Income Taxes - Reconciliation (Details)
Income Taxes - Tax Credit Carryover (Details)
Income Taxes - Tax Provision (Details)
Insider Trading Arrangements
Net Loss Per Share Attributable To Common Stockholders
Net Loss Per Share Attributable To Common Stockholders (Details)
Net Loss Per Share Attributable To Common Stockholders (Tables)
Net Loss Per Share Attributable To Common Stockholders - Excluded From Calculation (Details)
Organization And Business
Organization And Business (Details)
Organization And Business - Liquidity And Going Concern (Details)
Organization And Business - Nasdaq Communication And Compliance (Details)
Pay Vs Performance Disclosure
Preferred Stock
Preferred Stock (Details)
Preferred Stock (Tables)
Preferred Stock - Series E Preferred Stock (Details)
Preferred Stock - Series F Preferred Stock (Details)
Preferred Stock - Series G Preferred Stock (Details)
Preferred Stock - Series H Preferred Stock (Details)
Preferred Stock - Series I Preferred Stock (Details)
Related Party Transactions
Related Party Transactions - Bod Cash Compensation (Details)
Segment Data
Segment Data (Details)
Segment Data (Tables)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - 401(K) Plan (Details)
Stock-Based Compensation - Stock-Based Compensation (Details)
Stock-Based Compensation - Summary Of Stock Incentive Plans (Details)
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity - Reserved Shares And Common Stock (Details)
Stockholders' Equity - Reverse Stock Split And Atm (Details)
Stockholders' Equity- Noncontrolling Interest (Details)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Accounts Receivable And Concentrations (Details)
Summary Of Significant Accounting Policies - Comprehensive Loss (Details)
Summary Of Significant Accounting Policies - Inventory (Details)
Summary Of Significant Accounting Policies - Non-Controlling Interest (Details)
Summary Of Significant Accounting Policies - Property And Equipment And Indefinite-Lived Intangible Assets (Details)
Summary Of Significant Accounting Policies - Revenue Recognition (Details)
Summary Of Significant Accounting Policies - Revenue Recognition - Collaboration Revenue (Details)
Warrants
Warrants (Tables)
Warrants - Agreements 2 (Details)
Warrants - Warrants Outstanding And Exercisable (Details)
Ticker: JAGX
CIK: 1585608
Form Type: 10-K Annual Report
Accession Number: 0001558370-24-004439
Submitted to the SEC: Mon Apr 01 2024 6:57:23 AM EST
Accepted by the SEC: Mon Apr 01 2024
Period: Sunday, December 31, 2023
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/jagx/0001558370-24-004439.htm